Please use this identifier to cite or link to this item: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3482
Journal Title: FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
Authors: Paz-Ares, Luis
Spigel, David R.
Chen, Yuanbin
Jove, Maria
Juan-Vidal, Oscar
Rich, Patricia
Hayes, Theresa M.
Gutiérrez Calderón, Vanesea
Caro, Reyes Bernabe
Navarro, Alejandro
Dowlati, Afshin
Zhang, Bin
Moore, Yan
Yao, Xiaopan
Kokhreidze, Jaba
Ponce, Santiago
Bunn, Paul
SWH Author: Hayes, Theresa M.
Issue Date: 2021
Date Accessioned: 2023-03-17T04:57:11Z
Date Available: 2023-03-17T04:57:11Z
Url: https://dx.doi.org/10.1016/j.jtho.2021.01.126
Source Volume: 16
Issue Number: 3
DOI: 10.1016/j.jtho.2021.01.126
Abstract: Introduction Many patients with small cell lung cancer (SCLC) develop drug resistance to first-line platinum-based chemotherapy, and second-line therapies are limited. RESILIENT (ClinicalTrials.gov identifier NCT03088813) is a two-part phase 2/3 study assessing the safety, tolerability and efficacy of liposomal irinotecan monotherapy as second-line treatment for patients with SCLC. Here we report data from part 1 of the RESILIENT study (data cut off, 2 December 2019).
URI: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3482
Journal Title: Journal of Thoracic Oncology
Type: Journal Article
Appears in Collections:SWH Staff Publications



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing